SLDB — Solid Biosciences Income Statement
0.000.00%
Last trade - 00:00
- $328.48m
- $206.55m
- 30
- 16
- 95
- 44
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 13.6 | 8.09 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 119 | 88.4 | 85.9 | 96.3 | 104 |
Operating Profit | -119 | -88.4 | -72.3 | -88.2 | -104 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -117 | -88.3 | -72.2 | -86 | -96 |
Net Income After Taxes | -117 | -88.3 | -72.2 | -86 | -96 |
Net Income Before Extraordinary Items | |||||
Net Income | -117 | -88.3 | -72.2 | -86 | -96 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -117 | -88.3 | -72.2 | -86 | -96 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -43.6 | -24.9 | -10.1 | -10.8 | -4.81 |